| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802615701024 | 261570102 | CERTICAN TAB 0,25MG/TAB BTx60 (BLIST.6x10) | 85.39 | 89.58 | 113.95 |
| 05/2018 | 2802615702021 | 261570202 | CERTICAN TAB 0,5MG/TAB BTx60 (BLIST.6x10) | 170.80 | 179.17 | 216.51 |
| 05/2018 | 2802615703028 | 261570302 | CERTICAN TAB 0,75MG/TAB BTx60 (BLIST.6x10) | 266.34 | 270.34 | 320.95 |
| 05/2018 | 2802615704025 | 261570402 | CERTICAN TAB 1MG/TAB BTx60 BLIST.6x10) | 404.47 | 410.54 | 474.34 |
Investigated for use/treatment in transplant (rejection) and renal cell carcinoma.
Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.
After a single dose of radiolabeled everolimus was given to transplant patients receiving cyclosporine, the majority (80%) of radioactivity was recovered from the feces and only a minor amount (5%) was excreted in urine.